Card15 mutations and gastric cancer in a Portuguese population

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Jooste V, Remontet L, Colonna M, Belot A, Launoy G, Binder F, et al. Trends in the incidence of digestive cancers in France between 1980 and 2005 and projections for the year 2010. Eur J Cancer Prev 2011;20:375–80.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10; 2010. http://globocan.iarc.fr.
   Google Scholar
• Keighley MR. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 2003;18:7–30.
   PubMed Web of Science ®Google Scholar
• Bornschein J, Kandulski A, Selgrad M, Malfertheiner P. From gastric inflammation to gastric cancer. Dig Dis 2010;28:609–14.
   PubMed Web of Science ®Google Scholar
• Helicobacter and Cancer Collaborative Group. 2001;Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347–53.
   PubMed Web of Science ®Google Scholar
• Milne AN, Carneiro F, O'Morain C, Offerhaus GJ. Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 2009;126:615–28.
   PubMed Web of Science ®Google Scholar
• Hudler P. Genetic aspects of gastric cancer instability. ScientificWorldJournal 2012;2012:761909.
   PubMed Web of Science ®Google Scholar
• Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett 2008;266:99–115.
   PubMed Web of Science ®Google Scholar
• Mastoraki A, Danias N, Arkadopoulos N, Sakorafas G, Vasiliou P, Smyrniotis V. Prophylactic total gastrectomy for hereditary diffuse gastric cancer. Review of the literature. Surg Oncol 2011;20:e223–6.
   Google Scholar
• Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1–9.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Shiota S, Yamaoka Y. Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori. Infect Genet Evol 2012;12:203–13.
   PubMed Web of Science ®Google Scholar
• Hnatyszyn A, Szalata M, Stanczyk J, Cichy W, Slomski R. Association of c.802C>T polymorphism of NOD2/CARD15 gene with the chronic gastritis and predisposition to cancer in H. pylori infected patients. Exp Mol Pathol 2010;88:388–93.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang L, Jiang JM, Ma D, Tao HX, Yuan SL, et al. Association of NOD1 and NOD2 genes polymorphisms with Helicobacter pylori related gastric cancer in a Chinese population. World J Gastroenterol 2012;18:2112–20.
   PubMed Web of Science ®Google Scholar
• Tsang YH, Lamb A, Chen LF. New insights into the inactivation of gastric tumor suppressor RUNX3: the role of H. pylori infection. J Cell Biochem 2011;112:381–6.
   PubMed Web of Science ®Google Scholar
• Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175–86.
   PubMed Web of Science ®Google Scholar
• Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol 2007;21:281–97.
   PubMed Web of Science ®Google Scholar
• Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–9.
   PubMed Web of Science ®Google Scholar
• Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004;113:321–33.
   PubMed Web of Science ®Google Scholar
• Höcker M, Hohenberger P. Helicobacter pylori virulence factors–one part of a big picture. Lancet 2003;362:1231–3.
   PubMed Web of Science ®Google Scholar
• Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science 1999;284:1313–18.
   PubMed Web of Science ®Google Scholar
• Ponder BA. Cancer genetics. Nature 2001;411:336–41.
   PubMed Web of Science ®Google Scholar
• Peto J, Houlston RS. Genetics and the common cancers. Eur J Cancer 2001;37:S88–96.
   PubMed Web of Science ®Google Scholar
• Macarthur M, Hold GL, El-Omar EM. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004;286:G515–20.
   PubMed Web of Science ®Google Scholar
• Smith MG, Hold GL, Tahara E, El-Omar EM. Cellular and molecular aspects of gastric cancer. World J Gastroenterol 2006;12:2979–90.
   PubMed Web of Science ®Google Scholar
• Angeletti S, Galluzzo S, Santini D, Ruzzo A, Vincenzi B, Ferraro E, et al. NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population. Hum Immunol 2009;70:729–32.
   PubMed Web of Science ®Google Scholar
• Wex T, Ebert MP, Kropf S, Dierkes J, Schüttler K, Röcken C, et al. Gene polymorphisms of the NOD-2/CARD-15 gene and the risk of gastric cancer in Germany. Anticancer Res 2008;28:757–62.
   PubMed Web of Science ®Google Scholar
• Williams L, Jenkins GJ, Doak SH, Fowler P, Parry EM, Brown TH, et al. Fluorescence in situ hybridisation analysis of chromosomal aberrations in gastric tissue: the potential involvement of Helicobacter pylori. Br J Cancer 2005;92:1759–66.
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 2001;412:99.
   PubMed Web of Science ®Google Scholar
• Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003;125:364–71.
   PubMed Web of Science ®Google Scholar
• Xue H, Lin B, An J, Zhu Y, Huang G. Interleukin-10-819 promoter polymorphism in association with gastric cancer risk. BMC Cancer 2012;12:102.
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003;124:1193–201.
   PubMed Web of Science ®Google Scholar
• Yuzhalin A. The role of interleukin DNA polymorphisms in gastric cancer. Hum Immunol 2011;72:1128–36.
   PubMed Web of Science ®Google Scholar
• Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol 2010;25:1604–17.
   PubMed Web of Science ®Google Scholar
• Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 2008;154:360–4.
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599–603.
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603–6.
   PubMed Web of Science ®Google Scholar
• Lesage S, Zouali H, Cézard JP, Colombel JF, Belaiche J, Almer S, et al. EPWG-IBD Group; EPIMAD Group; GETAID Group. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845–57.
   PubMed Web of Science ®Google Scholar
• Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925–8.
   PubMed Web of Science ®Google Scholar
• Heliö T, Halme L, Lappalainen M, Fodstad H, Paavola- Sakki P, Turunen U, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003;52:558–62.
   PubMed Web of Science ®Google Scholar
• Kurzawski G, Suchy J, Kładny J, Grabowska E, Mierzejewski M, Jakubowska A, et al. The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res 2004;64:1604–6.
   PubMed Web of Science ®Google Scholar
• Papaconstantinou I, Theodoropoulos G, Gazouli M, Panoussopoulos D, Mantzaris GJ, Felekouras E, et al. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int J Cancer 2005;114:433–5.
   PubMed Web of Science ®Google Scholar
• Roberts RL, Gearry RB, Allington MD, Morrin HR, Robinson BA, Frizelle FA. Caspase recruitment domain- containing protein 15 mutations in patients with colorectal cancer. Cancer Res 2006;66:2532–5.
   PubMed Web of Science ®Google Scholar
• Möckelmann N, von Schönfels W, Buch S, von Kampen O, Sipos B, Egberts JH, et al. Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer. BMC Gastroenterol 2009;9:79.
   PubMed Web of Science ®Google Scholar
• Freire P, Portela F, Donato MM, Figueiredo P, Ferreira M, Amaro P, et al. CARD15 mutations and colorectal cancer in a South European country. Int J Colorectal Dis 2010;25:1211–19.
   PubMed Web of Science ®Google Scholar
• Rosenstiel P, Hellmig S, Hampe J, Ott S, Till A, Fischbach A, et al. Influence of polymorphisms in the NOD1/CARD4 and NOD2/CARD15 genes on the clinical outcome of Helicobacter pylori infection. Cell Microbiol 2006;8:1188–98.
   PubMed Web of Science ®Google Scholar
• Chiaravalli AM, Cornaggia M, Furlan D, Capella C, Fiocca R, Tagliabue G, et al. The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage. Virchows Arch 2001;439:158–69.
   PubMed Web of Science ®Google Scholar
• Werner M, Becker KF, Keller G, Höfler H. Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol 2001;127:207–16.
   PubMed Web of Science ®Google Scholar
• Straus EW, Patel H, Chang J, Gupta RM, Sottile V, Scirica J, et al. H. pylori infection and genotyping in patients undergoing upper endoscopy at inner city hospitals. Dig Dis Sci 2002;47:1575–81.
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Chow WH, Rabkin CS. Gastric cancer and H. pylori: Host genetics open the way. Gastroenterology 2001;121:1002–4.
   PubMed Web of Science ®Google Scholar
• Sepulveda AR, Peterson LE, Shelton J, et al. Predicting the risk of gastric cancer using H. pylori gastritis patterns associated with family history of gastric cancer (Abstract #42). Am J Hum Genet 2000;67:14.
   PubMed Web of Science ®Google Scholar
• Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ 2004:327–49.
   PubMedGoogle Scholar
• Ribeiro MM, Sarmento JA, Sobrinho Simões MA, Bastos J. Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma. Cancer 1981;47:780–4.
   PubMed Web of Science ®Google Scholar
• Pinheiro PS, Tyczyński JE, Bray F, Amado J, Matos E, Parkin DM. Cancer incidence and mortality in Portugal. Eur J Cancer 2003;39:2507–20.
   PubMed Web of Science ®Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.
   PubMedGoogle Scholar
• Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF, et al. Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch 2008;452:525–34.
   PubMed Web of Science ®Google Scholar
• Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402–5.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Bordin MC, Grehan N, Huntsman D, Suriano G, Machado JC, et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 2002;19:510–17.
   PubMed Web of Science ®Google Scholar
• The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1359–62.
   PubMed Web of Science ®Google Scholar
• Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. Science 1999;284:1328–33.
   PubMed Web of Science ®Google Scholar
• Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28–37.
   PubMed Web of Science ®Google Scholar
• Crabtree JE. Gastric mucosal inflammatory responses to Helicobacter pylori. Aliment Pharmacol Ther 1996;10:29–37.
   PubMed Web of Science ®Google Scholar
• Crusius JB, Canzian F, Capellá G, Peña AS, Pera G, Sala N, et al. Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol 2008;19:1894–902.
   PubMed Web of Science ®Google Scholar
• Ando T, Goto Y, Maeda O, Watanabe O, Ishiguro K, Goto H. Causal role of Helicobacter pylori infection in gastric cancer. World J Gastroenterol 2006;12:181–6.
   PubMed Web of Science ®Google Scholar
• Hamajima N, Naito M, Kondo T, Goto Y. Genetic factors involved in the development of Helicobacter pylori-related gastric cancer. Cancer Sci 2006;97:1129–38.
   PubMed Web of Science ®Google Scholar
• Rocco A, Nardone G. Diet, H pylori infection and gastric cancer: evidence and controversies. World J Gastroenterol 2007;13:2901–12.
   PubMed Web of Science ®Google Scholar
• Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005;307:734–8.
   PubMed Web of Science ®Google Scholar
• Alhopuro P, Ahvenainen T, Mecklin JP, Juhola M, Järvinen HJ, Karhu A, et al. NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res 2004;64:7245–7.
   PubMed Web of Science ®Google Scholar
• Tuupanen S, Alhopuro P, Mecklin JP, Järvinen H, Aaltonen LA. No evidence for association of NOD2 R702W and G908R with colorectal cancer. Int J Cancer 2007;121:76–9.
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Hitre E, Szalay F, Zinober K, Fuszek P, Lakatos L, et al. Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients. BMC Cancer 2007;7:54.
   PubMed Web of Science ®Google Scholar
• Arnott ID, Nimmo ER, Drummond HE, Fennell J, Smith BR, MacKinlay E, et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun 2004;5:417–25.
   PubMed Web of Science ®Google Scholar
• Croucher PJ, Mascheretti S, Hampe J, Huse K, Frenzel H, Stoll M, et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 2003;11:6–16.
   PubMed Web of Science ®Google Scholar
• Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 2006;367:1271–84.
   PubMed Web of Science ®Google Scholar
• Lim B, Ju H, Kim M, Kang C. Increased genetic susceptibility to intestinal-type gastric cancer is associated with increased activity of the RUNX3 distal promoter. Cancer 2011;117:5161–71.
   PubMed Web of Science ®Google Scholar
• Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, Schreiber S, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009;7:972–980.e2.
   PubMed Web of Science ®Google Scholar
• Annese V, Lombardi G, Perri F, D'Incà R, Ardizzone S, Riegler G, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease–an IG-IBD study. Am J Gastroenterol 2005;100:84–92.
   PubMed Web of Science ®Google Scholar
• Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002;359:1661–5.
   PubMed Web of Science ®Google Scholar
• Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679–88.
   PubMed Web of Science ®Google Scholar
• Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a meta-analysis. Am J Gastroenterol 2004;99:2393–404.
   PubMed Web of Science ®Google Scholar
• Radford-Smith G, Pandeya N. Associations between NOD2/CARD15 genotype and phenotype in Crohn's disease–Are we there yet? World J Gastroenterol 2006;12:7097–103.
   PubMed Web of Science ®Google Scholar
• Allen JI. Molecular biology of colon polyps and colon cancer. Semin Surg Oncol 1995;11:399–405.
   PubMed Web of Science ®Google Scholar